Traitement médicamenteux de la sclérose en plaques en Turquie — recevez 3 correspondances personnalisées de cliniques

Disease-modifying therapies for multiple sclerosis in Turkey are safe and adhere to global specialty standards. Medications like Ocrelizumab and Mavenclad are regulated by the Ministry of Health and administered in JCI-accredited centers. Specialist neurologists conduct rigorous pre-treatment screenings and monthly monitoring to manage potential side effects and long-term risks.

• Regulatory oversight: The Ministry of Health approves all DMTs, ensuring medications match European and US safety profiles.
• Specialized monitoring: Protocols include monthly blood counts, liver enzyme tests, and annual MRI scans for safety tracking.
• High-efficacy access: Accredited centers provide rapid access to infusion therapies like Ocrevus under strict administration guidelines.
• Infusion safety: Documented patient adherence for infusion therapies reaches 96.6%, significantly reducing the risk of complications.

Bookimed Expert Insight: Turkish clinics like NP Istanbul Brain Hospital integrate neuropsychiatric monitoring directly into MS care. This is a critical safety advantage many international patients overlook. They track cognitive changes and mood alongside physical symptoms. This dual-focus approach ensures that side effects affecting mental clarity are caught much earlier than in standard neurology settings.

Patient Consensus: Patients value the speed of starting high-efficacy treatments like Ocrevus, which often begins within weeks of diagnosis. They emphasize the importance of keeping personal logs for liver enzyme spikes and following the mandatory Ministry-approved screening protocols.

Multiple sclerosis medications in Turkey demonstrate up to 70% success in reducing relapses and slowing disease progression. High-efficacy treatments like Ocrevus (ocrelizumab) achieve a 94-95% reduction in brain lesions, while oral therapies such as fingolimod decrease annualized relapse rates by approximately 48% to 53%.

• High-efficacy infusions: Ocrevus reduces relapse risk by 47% compared to traditional interferon treatments.
• Oral medication results: Dimethyl fumarate shows a 44-53% reduction in relapses and 38% slower progression.
• Stem cell efficacy: Specialized hematology centers report 70% improvement in neurological function for eligible patients.
• Adherence rates: Intravenous infusion therapies maintain the highest patient adherence levels at 96.6%.

Bookimed Expert Insight: Patients at JCI-accredited centers like NP Istanbul Brain Hospital or Memorial Şişli often access Ocrevus for $10,000 to $15,000. This is significantly lower than the $18,500 US average. Expert neurologists like Dr. Baris Topcular at Istanbul Florence Nightingale Hospital integrate advanced Brain PET imaging to monitor these high-efficacy drugs. This specific imaging technology allows for much earlier detection of treatment failure than standard MRI protocols used in smaller clinics.

Patient Consensus: Patients report 70-90% relapse reduction with Ocrevus but suggest monitoring for infusion reactions. Those using oral therapies recommend a low-dose taper with aspirin to manage common flushing and gastrointestinal side effects.

Candidates for high-efficacy disease-modifying therapies in Turkey typically include patients with highly active relapsing-remitting multiple sclerosis. Eligibility focuses on those under 40 with two or more annual relapses or significant MRI lesion burden. Specialists prioritize these treatments to prevent irreversible neurological damage in aggressive cases.

• Clinical criteria: Includes patients experiencing multiple disabling relapses within a single year.
• Radiological markers: Eligibility often requires 9 or more lesions or active gadolinium-enhancing lesions.
• Age factors: Patients under 40 are prioritized for early intensive treatment to preserve function.
• Diagnostic tools: High-efficacy DMT eligibility is confirmed via McDonald Criteria and rigorous MRI monitoring.

Bookimed Expert Insight: While the government-subsidized SGK pathway usually requires failing first-line drugs like interferons, private clinics in Istanbul offer immediate access to Ocrevus or Natalizumab. Choosing a JCI-accredited facility like NP Istanbul Brain Hospital allows patients to bypass long committee wait times and start aggressive treatment months earlier.

Patient Consensus: Patients recommend bringing a detailed relapse diary and baseline MRI scans to quantify disease activity quickly. Many emphasize that starting high-efficacy drugs early was easier when bypassing public health bureaucracy via private consultations.